Grecale
Timing that's it
- Registrato
- 19/5/03
- Messaggi
- 12.596
- Punti reazioni
- 1.503
Drrx
- Creatore Discussione Grecale
- Data di inizio
-
Ecco la 66° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.
I principali indici azionari hanno vissuto una settimana turbolenta, caratterizzata dalla riunione della Fed, dai dati macro importanti e dagli utili societari di alcune big tech Usa. Mercoledì scorso la Fed ha confermato i tassi di interesse e ha sostanzialmente escluso un aumento. Tuttavia, Powell e colleghi potrebbero lasciare il costo del denaro su livelli restrittivi in mancanza di progressi sul fronte dei prezzi. Inoltre, i dati di oggi sul mercato del lavoro Usa hanno mostrato dei segnali di raffreddamento. Per continuare a leggere visita il link
oggi earnings
ffaiper
nvediCOMEballaNASQAD
- Registrato
- 8/12/02
- Messaggi
- 1.583
- Punti reazioni
- 6
CUPERTINO, Calif., April 14 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX - News) first quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, April 22, 2004 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer and Tom Schreck, Chief Financial Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
What: DURECT Corporation's First Quarter 2004 Earnings Conference Call
When: Thursday, April 22nd, 2004, 4:30 p.m. EDT
Where: www.durect.com and click 'Investor Relations'
Live over the Internet -- Simply log on to the Web at the
address listed above.
stasera conference call,,,
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
What: DURECT Corporation's First Quarter 2004 Earnings Conference Call
When: Thursday, April 22nd, 2004, 4:30 p.m. EDT
Where: www.durect.com and click 'Investor Relations'
Live over the Internet -- Simply log on to the Web at the
address listed above.
stasera conference call,,,
tremaui
KA MATE KA ORA!!
- Registrato
- 26/8/00
- Messaggi
- 2.325
- Punti reazioni
- 109
*DJ DURECT Corp 1Q Loss 12c/Shr >DRRX [DHKVXZR]
(MORE) Dow Jones Newswires
04-22-04 1606ET- - 04 06 PM EDT 04-22-04
----------------------------------------------------------------------------
DURECT Corporation Announces First Quarter 2004 Financial Results [DHKVXXG]
/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/
-- WITH LOGO -- TO BUSINESS, HEALTH AND MEDICAL EDITORS:
DURECT Corporation Announces First Quarter 2004 Financial Results
CUPERTINO, Calif., April 22 /PRNewswire-FirstCall/ -- DURECT Corporation
(Nasdaq: DRRX) announced today financial results for the three months ended
March 31, 2004.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
DURECT's net loss for the three months ended March 31, 2004 was
$6.0 million or 12 cents per share, compared to a net loss of $5.9 million or
12 cents per share for the same period in 2003. DURECT's results for the three
months ended March 31, 2004 included non-cash charges for the amortization of
intangible assets and stock-based compensation of $370,000, compared to
$181,000 for the same period in 2003. Cash used in operating activities was
$4.7 million for the three months ended March 31, 2004, compared to
$5.2 million for the same period in 2003.
"During the quarter, the Company completed feasibility studies to test and
measure the performance of a number of alternative prototype systems in
animals for our CHRONOGESIC(R) product, which we have partnered with Endo
Pharmaceuticals in the U.S. and Canada. Based on the data, we have identified
a number of possible solutions to address the premature shutdown. The results
thus far give us the confidence that this program remains on track, and we
anticipate that we will resume human clinical trials by the end of the year as
previously stated," stated James E. Brown, DVM, President and CEO of DURECT.
Dr. Brown continued, "Additionally, we have been formulating our SABER(TM)
post-operative pain relief depot product with higher drug loadings in
preparation for Phase I/IIA studies anticipated later this year. We are also
formulating different compositions for different clinical settings. We held a
clinical advisory meeting with our Scientific Advisory Board composed of
relevant physician experts and thought leaders, where they provided valuable
input into our Phase I/IIA clinical trial protocol design. We are very pleased
at the level of interest that this product has received from our clinical
advisors, potential partners and physicians currently treating patients who
would be targeted for our product."
"During the quarter, Phase I clinical testing began for Remoxy(TM), a
novel long-acting oral formulation of oxycodone that utilizes our SABER
technology and which is targeted to decrease the potential for oxycodone
abuse. This product is partnered with Pain Therapeutics, Inc., and we look
forward to the clinical results from this program."
Total revenues were $3.4 million for the three months ended March 31,
2004, compared to $2.6 million for the same period in 2003. Total
collaborative research and development and other revenues were $2.0 million
for the three months ended March 31, 2004, compared with $1.1 million for the
same period in 2003. The increase in total revenues was primarily attributable
to higher collaborative research and development revenue recognized from our
agreements with Pain Therapeutics, Inc. and Voyager Pharmaceutical Corporation
and higher service revenue from our wholly-owned subsidiary, Absorbable
Polymers International Corporation (API), offset by lower product revenues
from our ALZET(R) and API product lines.
Research and development expenses were $5.4 million for the three months
ended March 31, 2004, compared to $5.6 million for the same period in 2003.
The decrease in the three months ended March 31, 2004 was primarily
attributable to the lower personnel expenses and consulting expenses compared
with the same period in 2003.
Selling, general and administrative expenses were $2.2 million for the
three months ended March 31, 2004, compared to $2.2 million for the same
period in 2003. There was no material difference in selling, general and
administrative expenses between the quarter ended March 31, 2004 and the
quarter ended March 31, 2003.
Interest income was $304,000 for the three months ended March 31, 2004,
compared with $241,000 for the same period in 2003. The increase in interest
income was primarily the result of higher cash and investment balances held
during the three months ended March 31, 2004, partially offset by a decline in
interest rates. Interest expense was $1.1 million for the three months ended
March 31, 2004 as compared to $124,000 for the same period in 2003. The
increase during the three months ended March 31, 2004 was primarily the result
of the interest accrued on the $60.0 million convertible notes the Company
issued in June and July of 2003.
At March 31, 2004, DURECT had cash and investments of $80.3 million,
including $3.0 million in restricted investments, compared with cash and
investments of $85.2 million at December 31, 2003.
DURECT expects its net loss for the second quarter of 2004 will range from
$7.0 million to $8.0 million or 14 to 16 cents per share.
(MORE) Dow Jones Newswires
04-22-04 1606ET- - 04 06 PM EDT 04-22-04
----------------------------------------------------------------------------
DURECT Corporation Announces First Quarter 2004 Financial Results [DHKVXXG]
/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/
-- WITH LOGO -- TO BUSINESS, HEALTH AND MEDICAL EDITORS:
DURECT Corporation Announces First Quarter 2004 Financial Results
CUPERTINO, Calif., April 22 /PRNewswire-FirstCall/ -- DURECT Corporation
(Nasdaq: DRRX) announced today financial results for the three months ended
March 31, 2004.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
DURECT's net loss for the three months ended March 31, 2004 was
$6.0 million or 12 cents per share, compared to a net loss of $5.9 million or
12 cents per share for the same period in 2003. DURECT's results for the three
months ended March 31, 2004 included non-cash charges for the amortization of
intangible assets and stock-based compensation of $370,000, compared to
$181,000 for the same period in 2003. Cash used in operating activities was
$4.7 million for the three months ended March 31, 2004, compared to
$5.2 million for the same period in 2003.
"During the quarter, the Company completed feasibility studies to test and
measure the performance of a number of alternative prototype systems in
animals for our CHRONOGESIC(R) product, which we have partnered with Endo
Pharmaceuticals in the U.S. and Canada. Based on the data, we have identified
a number of possible solutions to address the premature shutdown. The results
thus far give us the confidence that this program remains on track, and we
anticipate that we will resume human clinical trials by the end of the year as
previously stated," stated James E. Brown, DVM, President and CEO of DURECT.
Dr. Brown continued, "Additionally, we have been formulating our SABER(TM)
post-operative pain relief depot product with higher drug loadings in
preparation for Phase I/IIA studies anticipated later this year. We are also
formulating different compositions for different clinical settings. We held a
clinical advisory meeting with our Scientific Advisory Board composed of
relevant physician experts and thought leaders, where they provided valuable
input into our Phase I/IIA clinical trial protocol design. We are very pleased
at the level of interest that this product has received from our clinical
advisors, potential partners and physicians currently treating patients who
would be targeted for our product."
"During the quarter, Phase I clinical testing began for Remoxy(TM), a
novel long-acting oral formulation of oxycodone that utilizes our SABER
technology and which is targeted to decrease the potential for oxycodone
abuse. This product is partnered with Pain Therapeutics, Inc., and we look
forward to the clinical results from this program."
Total revenues were $3.4 million for the three months ended March 31,
2004, compared to $2.6 million for the same period in 2003. Total
collaborative research and development and other revenues were $2.0 million
for the three months ended March 31, 2004, compared with $1.1 million for the
same period in 2003. The increase in total revenues was primarily attributable
to higher collaborative research and development revenue recognized from our
agreements with Pain Therapeutics, Inc. and Voyager Pharmaceutical Corporation
and higher service revenue from our wholly-owned subsidiary, Absorbable
Polymers International Corporation (API), offset by lower product revenues
from our ALZET(R) and API product lines.
Research and development expenses were $5.4 million for the three months
ended March 31, 2004, compared to $5.6 million for the same period in 2003.
The decrease in the three months ended March 31, 2004 was primarily
attributable to the lower personnel expenses and consulting expenses compared
with the same period in 2003.
Selling, general and administrative expenses were $2.2 million for the
three months ended March 31, 2004, compared to $2.2 million for the same
period in 2003. There was no material difference in selling, general and
administrative expenses between the quarter ended March 31, 2004 and the
quarter ended March 31, 2003.
Interest income was $304,000 for the three months ended March 31, 2004,
compared with $241,000 for the same period in 2003. The increase in interest
income was primarily the result of higher cash and investment balances held
during the three months ended March 31, 2004, partially offset by a decline in
interest rates. Interest expense was $1.1 million for the three months ended
March 31, 2004 as compared to $124,000 for the same period in 2003. The
increase during the three months ended March 31, 2004 was primarily the result
of the interest accrued on the $60.0 million convertible notes the Company
issued in June and July of 2003.
At March 31, 2004, DURECT had cash and investments of $80.3 million,
including $3.0 million in restricted investments, compared with cash and
investments of $85.2 million at December 31, 2003.
DURECT expects its net loss for the second quarter of 2004 will range from
$7.0 million to $8.0 million or 14 to 16 cents per share.
Grecale
Timing that's it
- Registrato
- 19/5/03
- Messaggi
- 12.596
- Punti reazioni
- 1.503
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.520
- Punti reazioni
- 1.153
un bel gap
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.520
- Punti reazioni
- 1.153
che dici Luciano
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.520
- Punti reazioni
- 1.153
va bene grazie.
Grecale
Timing that's it
- Registrato
- 19/5/03
- Messaggi
- 12.596
- Punti reazioni
- 1.503
DURECT Initiates Phase I Trial for Its Proprietary Transdermal Sufentanil Patch Related Stocks
DRRX
CUPERTINO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (DRRX - news) today announced the initiation of a phase I clinical trial for a new proprietary transdermal sufentanil product. The trial consists of a pharmacokinetic study in normal, healthy volunteers in Europe. The objectives of the clinical study are to determine the safety and tolerability of DURECT's transdermal sufentanil patch as well as evaluate the pharmacokinetics of sufentanil following transdermal administration. Sufentanil is a pain relief medication that is currently FDA-approved for use in hospitals as an analgesic and is the active ingredient in DURECT's CHRONOGESIC(R) product under development. DURECT's transdermal sufentanil product is intended to provide extended chronic pain relief for up to seven days, as compared to the three days of relief provided with currently available patches. Further, DURECT anticipates that the small size of the DURECT sufentanil patch (approximately 1/5th the size of current transdermal fentanyl patches for a therapeutically equivalent dose) may offer improved convenience for patients. Worldwide sales for DURAGESIC(R), a leading transdermal fentanyl product, exceeded $1.6 billion in 2003.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
Transdermal Sufentanil Patch Product Description
DURECT's sufentanil transdermal patch product potentially offers the following benefits over current transdermal fentanyl patches:
-- Increased duration of pain relief for up to seven days
-- Smaller patch size (approximately 1/5th the size of current transdermal
fentanyl patches for a therapeutically equivalent dose)
-- We anticipate that other potential benefits could be:
-- Improved convenience and patient compliance
-- Reduced skin irritation
-- Cosmetic and quality of life improvements
-- Improved patch adhesion
-- Easier for high dose patients who require multiple transdermal
patches
"In our Phase II study for our CHRONOGESIC product, where sufentanil is the active ingredient, the data showed 2-to-1 patient preference for the therapy, better pain control and an improved side effect profile when compared to other opioid medications on the market. We anticipate that some of these benefits will also be applicable to our transdermal sufentanil product," stated James E. Brown, DVM, President and CEO of DURECT. "We are leveraging the knowledge and infrastructure relating to sufentanil gained from our considerable work with this compound to the development of our transdermal product. We believe that our transdermal product will be additive and complementary to DURECT's other pain-related products currently under development."
American Society of Anesthesiologists (ASA) 2004 Annual Meeting Presentation
Pamela Palmer, M.D., Ph.D., Professor, Department of Anesthesiology and Peri-Operative Care, and Medical Director of the Pain Management Center at University of California, San Francisco (UCSF), will be delivering a presentation discussing several innovative approaches to pain management at this weekend's ASA meeting in Las Vegas, Nevada. The presentation, entitled "Pharmacologic Approaches to Pain Management," will highlight details of DURECT's transdermal sufentanil patch and will be made on Saturday, October 23, 2004 at 8:30 a.m. in rooms N115-116 at the Las Vegas Convention Center.
About DURECT Corporation
DURECT Corporation is a pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein and small molecule delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the DURING(TM) Biodegradable Implant (drug-loaded implant system) and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which three are in collaboration with pharmaceutical partners. Additional information about DURECT is available at http://www.durect.com/.
NOTE: SABER(TM), ORADUR(TM), DURIN(TM), MICRODUR(TM) and CHRONOGESIC(R) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.
The statements in this press release regarding DURECT's products in development, product development plans, anticipated clinical trials and potential markets are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's ability to complete the design, development, and manufacturing process development of these products, manufacture and commercialize these products, obtain product and manufacturing approvals from regulatory agencies as well as marketplace acceptance of these products. Further information regarding these and other risks is included in DURECT's Annual Report on Form 10-K for the fiscal year ended December 31, 2003 filed with the SEC on March 11, 2004, DURECT's Quarterly Report on Form 10-Q and other periodic reports filed with the SEC under the heading "Factors that may affect future results."
The transdermal sufentanil patch and CHRONOGESIC(R) products referred to in this press release are under development and have not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.
CONTACT: Schond L. Greenway, Executive Director, Investor Relations andStrategic Planning, of DURECT Corporation, +1-408-777-1417; or investors,Stephanie C. Diaz, +1-415-885-2298, or sdiaz@vidaLLC.com, or media, Tim Brons,+1-646-319-8981, or tbrons@vidaLLC.com, both of Vida Communication
Web site: http://www.durect.com/
DRRX
CUPERTINO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (DRRX - news) today announced the initiation of a phase I clinical trial for a new proprietary transdermal sufentanil product. The trial consists of a pharmacokinetic study in normal, healthy volunteers in Europe. The objectives of the clinical study are to determine the safety and tolerability of DURECT's transdermal sufentanil patch as well as evaluate the pharmacokinetics of sufentanil following transdermal administration. Sufentanil is a pain relief medication that is currently FDA-approved for use in hospitals as an analgesic and is the active ingredient in DURECT's CHRONOGESIC(R) product under development. DURECT's transdermal sufentanil product is intended to provide extended chronic pain relief for up to seven days, as compared to the three days of relief provided with currently available patches. Further, DURECT anticipates that the small size of the DURECT sufentanil patch (approximately 1/5th the size of current transdermal fentanyl patches for a therapeutically equivalent dose) may offer improved convenience for patients. Worldwide sales for DURAGESIC(R), a leading transdermal fentanyl product, exceeded $1.6 billion in 2003.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
Transdermal Sufentanil Patch Product Description
DURECT's sufentanil transdermal patch product potentially offers the following benefits over current transdermal fentanyl patches:
-- Increased duration of pain relief for up to seven days
-- Smaller patch size (approximately 1/5th the size of current transdermal
fentanyl patches for a therapeutically equivalent dose)
-- We anticipate that other potential benefits could be:
-- Improved convenience and patient compliance
-- Reduced skin irritation
-- Cosmetic and quality of life improvements
-- Improved patch adhesion
-- Easier for high dose patients who require multiple transdermal
patches
"In our Phase II study for our CHRONOGESIC product, where sufentanil is the active ingredient, the data showed 2-to-1 patient preference for the therapy, better pain control and an improved side effect profile when compared to other opioid medications on the market. We anticipate that some of these benefits will also be applicable to our transdermal sufentanil product," stated James E. Brown, DVM, President and CEO of DURECT. "We are leveraging the knowledge and infrastructure relating to sufentanil gained from our considerable work with this compound to the development of our transdermal product. We believe that our transdermal product will be additive and complementary to DURECT's other pain-related products currently under development."
American Society of Anesthesiologists (ASA) 2004 Annual Meeting Presentation
Pamela Palmer, M.D., Ph.D., Professor, Department of Anesthesiology and Peri-Operative Care, and Medical Director of the Pain Management Center at University of California, San Francisco (UCSF), will be delivering a presentation discussing several innovative approaches to pain management at this weekend's ASA meeting in Las Vegas, Nevada. The presentation, entitled "Pharmacologic Approaches to Pain Management," will highlight details of DURECT's transdermal sufentanil patch and will be made on Saturday, October 23, 2004 at 8:30 a.m. in rooms N115-116 at the Las Vegas Convention Center.
About DURECT Corporation
DURECT Corporation is a pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein and small molecule delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the DURING(TM) Biodegradable Implant (drug-loaded implant system) and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which three are in collaboration with pharmaceutical partners. Additional information about DURECT is available at http://www.durect.com/.
NOTE: SABER(TM), ORADUR(TM), DURIN(TM), MICRODUR(TM) and CHRONOGESIC(R) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.
The statements in this press release regarding DURECT's products in development, product development plans, anticipated clinical trials and potential markets are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's ability to complete the design, development, and manufacturing process development of these products, manufacture and commercialize these products, obtain product and manufacturing approvals from regulatory agencies as well as marketplace acceptance of these products. Further information regarding these and other risks is included in DURECT's Annual Report on Form 10-K for the fiscal year ended December 31, 2003 filed with the SEC on March 11, 2004, DURECT's Quarterly Report on Form 10-Q and other periodic reports filed with the SEC under the heading "Factors that may affect future results."
The transdermal sufentanil patch and CHRONOGESIC(R) products referred to in this press release are under development and have not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.
CONTACT: Schond L. Greenway, Executive Director, Investor Relations andStrategic Planning, of DURECT Corporation, +1-408-777-1417; or investors,Stephanie C. Diaz, +1-415-885-2298, or sdiaz@vidaLLC.com, or media, Tim Brons,+1-646-319-8981, or tbrons@vidaLLC.com, both of Vida Communication
Web site: http://www.durect.com/